News

December 11, 2019

Single-Blinded Trial Design Prevents Patients From Withdrawing Prematurely, Analysis Shows

News

BeyondSpring’s single-blinded trial design, in which patients are unaware of the treatment they receive, effectively prevented participants from prematurely withdrawing from the company’s DUBLIN-3 study due to dissatisfaction with ... Read more

December 9, 2019

FDA Grants N-803 Combo Breakthrough Therapy Status for Non-Muscle Invasive Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ImmunityBio‘s interleukin-15 (IL-15) agonist N-803, in combination with Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle ... Read more

December 5, 2019December 6, 2019

Tecentriq-chemo Combo OK’d as First-line Treatment for Certain Metastatic NSCLC Patients

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with chemotherapy — Abraxane (nab-paclitaxel) plus carboplatin — as a first-line treatment for patients with metastatic non-squamous ... Read more

December 4, 2019

Bavencio First-line Maintenance Failed to Extend Survival in Patients with Advanced Gastric and GEJ Cancer

News

First-line maintenance therapy with Bavencio (avelumab) failed to extend the overall survival of patients with advanced stomach or gastroesophageal junction (GEJ) cancer, as compared to standard care, according to ... Read more

November 27, 2019November 27, 2019

Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers

News

Surface Oncology is requesting approval to open a Phase 1/1b clinical trial testing SRF617, an anti-CD39 antibody, either alone or in combination with other cancer immunotherapies in people with advanced solid tumors. ... Read more

November 15, 2019December 5, 2019

Treatment With VBI-1901 Linked to Tumor Stabilization in Recurrent Gliobastoma Patients in Phase 1/2 Trial

News

Immune responses triggered by the investigational cancer vaccine VBI-1901 correlate with the stabilization of tumor size in patients with recurrent glioblastoma (GBM), a common and aggressive brain cancer, according ... Read more

November 13, 2019

CytomX Initiates Phase 2 Trial Testing CX-072, Yervoy Combo in Relapsed or Refractory Melanoma

News

CytomX Therapeutics has initiated a Phase 2 clinical trial to test a combination of its probody CX-072 — a type of engineered antibody — with Yervoy (ipilimumab) for treating ... Read more

November 11, 2019

2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show

News

Adding Imfinzi (durvalumab) — alone or in combination with tremelimumab — to standard first-line chemotherapy significantly delayed disease progression or death in people with metastatic non-small cell lung cancer (NSCLC), compared ... Read more

November 8, 2019

MDNA55 Increases Survival in Glioblastoma, Notably in Patients With High ILR4 Levels, Early Trial Data Show

News

The investigational therapy MDNA55 increases survival in people with recurrent glioblastoma, a type of brain cancer — especially in those who produce high levels of ILR4, a marker of ... Read more

November 6, 2019

Opdivo-Yervoy Plus Shorter Chemotherapy Course Extends Survival of Patients with Advanced Lung Cancer, Early Trial Data Show

News

First-line treatment with a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) added to a shorter course of chemotherapy significantly extends the survival of people with advanced non-small cell ... Read more

Pin It on Pinterest